Saranas Submits IPO Filing Following FDA Approval of Early Bird, the First Real-Time Endovascular Bleeding Monitoring System

VCBeat (WeChat ID: vcbeat) has learned that Early Bird, an early intravascular hemorrhage monitoring device developed by Saranas, has recently received approval from the U.S. Food and Drug Administration (FDA). Currently, Early Bird is undergoing pilot programs in multiple regions across the United States to evaluate its ability to monitor hemorrhage during vascular interventions and enhance patient safety. Moving forward, Saranas will promote the device throughout the U.S. market.

Saranas, founded in 2011, is a medical device company dedicated to real-time monitoring of bleeding during endovascular procedures. The company’s Early Bird system is the first and only early bleeding detection device on the market, enabling physicians to immediately identify and address bleeding events. This technology significantly reduces bleeding-related complications, lowers associated healthcare costs, and improves patient outcomes.

Early Bird features a vascular access sheath with embedded sensors that monitor for vascular bleeding during endovascular procedures by measuring changes in vascular resistance, such as in transcatheter aortic valve replacement (TAVR), large-bore hemodynamic support device placement, or other complex cardiovascular interventional procedures. In animal trials, the device demonstrated 100% sensitivity and 100% specificity in monitoring intravascular bleeding.

Each year, more than 20 million patients in the United States require endovascular procedures, among whom approximately 1 million experience severe bleeding complications. A sample survey conducted by Saranas on 17,000 U.S. patients who underwent large-bore transcatheter interventional procedures revealed that one in five patients experienced bleeding complications. In 2017, the Journal of the American Medical Association (JAMA) reported that following percutaneous interventions using large-bore catheters, patient mortality increased threefold, hospital stays were prolonged twofold, and costs for managing procedural bleeding rose by 60%.

Dimitrios Karmpaliotis, a physician at Columbia University Medical Center specializing in high-risk angioplasty, stated, “Intravascular hemorrhage is the Achilles’ heel of minimally invasive and catheter-based procedures. The Early Bird system’s real-time hemorrhage monitoring capability enables physicians to promptly detect bleeding, making it an indispensable tool in clinical practice.”

(Compiled by Jiao Yanli)